VC-backed Zosano files for IPO

Zosano Pharma Corp. said Tuesday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Based in Fremont, Calif., Zosano is a biopharmaceutical firm focused on transdermal drug delivery. Its backers include Nomura International, BioMed Ventures, HBM BioVentures, NEA and ProQuest Investments.

PRESS RELEASE

FREMONT, Calif., June 24, 2014 /PRNewswire/ — Zosano Pharma Corporation (Zosano) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The number of shares to be offered and the price range for the offering have not yet been determined.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Zosano Pharma Corporation
Zosano Pharma Corporation is a privately held biopharmaceutical company and a pioneer in the field of transdermal drug delivery. Zosano is developing products with a rapid onset using its proprietary microneedle patch system. Zosano seeks to develop products with significant commercial potential both independently and in collaboration with strategic partners. Zosano’s microneedle patch delivers therapeutic compounds through the skin and provides rapid systemic drug delivery in a convenient, needle–free and pain–free system. Zosano’s microneedle patch system has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.

Related Posts

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget